265 related articles for article (PubMed ID: 21799180)
21. MYCN repression of Lifeguard/FAIM2 enhances neuroblastoma aggressiveness.
Planells-Ferrer L; Urresti J; Soriano A; Reix S; Murphy DM; Ferreres JC; Borràs F; Gallego S; Stallings RL; Moubarak RS; Segura MF; Comella JX
Cell Death Dis; 2014 Sep; 5(9):e1401. PubMed ID: 25188511
[TBL] [Abstract][Full Text] [Related]
22. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738
[TBL] [Abstract][Full Text] [Related]
23. IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma.
Bell JL; Turlapati R; Liu T; Schulte JH; Hüttelmaier S
J Clin Oncol; 2015 Apr; 33(11):1285-93. PubMed ID: 25753434
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1.
Creevey L; Ryan J; Harvey H; Bray IM; Meehan M; Khan AR; Stallings RL
Mol Cancer; 2013 Mar; 12():23. PubMed ID: 23531080
[TBL] [Abstract][Full Text] [Related]
25. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
[TBL] [Abstract][Full Text] [Related]
26. Effects of 3β-acethyl tormentic acid (3ATA) on ABCC proteins activity.
Da Graça Rocha G; Simões M; Oliveira RR; Kaplan MAC; Gattass CR
Int J Mol Sci; 2012; 13(6):6757-6771. PubMed ID: 22837662
[TBL] [Abstract][Full Text] [Related]
27. Role of chemotherapy resistance genes in outcome of neuroblastoma.
de Cremoux P; Jourdan-Da-Silva N; Couturier J; Tran-Perennou C; Schleiermacher G; Fehlbaum P; Doz F; Mosseri V; Delattre O; Klijanienko J; Vielh P; Michon J
Pediatr Blood Cancer; 2007 Mar; 48(3):311-7. PubMed ID: 16609945
[TBL] [Abstract][Full Text] [Related]
28. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.
Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG
FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782
[TBL] [Abstract][Full Text] [Related]
29. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
[TBL] [Abstract][Full Text] [Related]
30. Nrf2 signaling increases expression of ATP-binding cassette subfamily C mRNA transcripts at the blood-brain barrier following hypoxia-reoxygenation stress.
Ibbotson K; Yell J; Ronaldson PT
Fluids Barriers CNS; 2017 Mar; 14(1):6. PubMed ID: 28298215
[TBL] [Abstract][Full Text] [Related]
31. Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells.
Chayka O; D'Acunto CW; Middleton O; Arab M; Sala A
J Biol Chem; 2015 Jan; 290(4):2198-212. PubMed ID: 25477524
[TBL] [Abstract][Full Text] [Related]
32. ABCC1 G2012T single nucleotide polymorphism is associated with patient outcome in primary neuroblastoma and altered stability of the ABCC1 gene transcript.
Pajic M; Murray J; Marshall GM; Cole SP; Norris MD; Haber M
Pharmacogenet Genomics; 2011 May; 21(5):270-9. PubMed ID: 21317832
[TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
[TBL] [Abstract][Full Text] [Related]
34. Dickkopf-3 expression is a marker for neuroblastic tumor maturation and is down-regulated by MYCN.
Koppen A; Ait-Aissa R; Koster J; Øra I; Bras J; van Sluis PG; Caron H; Versteeg R; Valentijn LJ
Int J Cancer; 2008 Apr; 122(7):1455-64. PubMed ID: 18059033
[TBL] [Abstract][Full Text] [Related]
35. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM
Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205
[TBL] [Abstract][Full Text] [Related]
36. Characterization of multidrug transporter-mediated efflux of avermectins in human and mouse neuroblastoma cell lines.
Dalzell AM; Mistry P; Wright J; Williams FM; Brown CD
Toxicol Lett; 2015 Jun; 235(3):189-98. PubMed ID: 25865432
[TBL] [Abstract][Full Text] [Related]
37. ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier.
Bronger H; König J; Kopplow K; Steiner HH; Ahmadi R; Herold-Mende C; Keppler D; Nies AT
Cancer Res; 2005 Dec; 65(24):11419-28. PubMed ID: 16357150
[TBL] [Abstract][Full Text] [Related]
38. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
39. Characterizing Iranian Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia Through Gene Expression Profiling of Common ATP Binding Cassette Transporters Subfamily C.
Mehrvar N; Abolghasemi H; Rezvany MR; Akbari ME; Saberynejad J; Mehrvar A; Movafagh A
J Pediatr Hematol Oncol; 2020 Jan; 42(1):41-45. PubMed ID: 31613845
[TBL] [Abstract][Full Text] [Related]
40. Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters.
Martin V; Xu J; Pabbisetty SK; Alonso MM; Liu D; Lee OH; Gumin J; Bhat KP; Colman H; Lang FF; Fueyo J; Gomez-Manzano C
Oncogene; 2009 Jun; 28(24):2358-63. PubMed ID: 19421150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
